At the time of writing, NeuroPace Inc [NPCE] stock is trading at $13.77, down -3.23%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The NPCE shares have gain 13.90% over the last week, with a monthly amount drifted -1.92%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
NeuroPace Inc [NASDAQ: NPCE] stock has seen the most recent analyst activity on January 21, 2025, when UBS initiated its Buy rating and assigned the stock a price target of $17. Previously, Wells Fargo upgraded its rating to Overweight on March 14, 2024, and elevated its price target to $20. On January 30, 2024, Leerink Partners initiated with a Outperform rating and assigned a price target of $22 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $11 on November 10, 2023. Morgan Stanley upgraded its rating to a Equal-Weight and raised its price target to $6 on August 24, 2023. Lake Street started tracking with a Buy rating for this stock on February 22, 2023, and assigned it a price target of $10. In a note dated April 06, 2022, Wolfe Research initiated an Outperform rating and provided a target price of $13 on this stock.
For the past year, the stock price of NeuroPace Inc fluctuated between $5.45 and $17.47. Currently, Wall Street analysts expect the stock to reach $12.88 within the next 12 months. NeuroPace Inc [NASDAQ: NPCE] shares were valued at $13.77 at the most recent close of the market. An investor can expect a potential drop of -6.46% based on the average NPCE price forecast.
Analyzing the NPCE fundamentals
According to NeuroPace Inc [NASDAQ:NPCE], the company’s sales were 76.45M for trailing twelve months, which represents an 28.20% jump. Gross Profit Margin for this corporation currently stands at 0.74% with Operating Profit Margin at -0.3%, Pretax Profit Margin comes in at -0.37%, and Net Profit Margin reading is -0.37%. To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -2.05 and Total Capital is -0.28. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of7.48.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.28 points at the first support level, and at 12.78 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.24, and for the 2nd resistance point, it is at 14.70.
Ratios To Look Out For
It is important to note that NeuroPace Inc [NASDAQ:NPCE] has a current ratio of 5.59. As well, the Quick Ratio is 4.77, while the Cash Ratio is 1.04. Considering the valuation of this stock, the price to sales ratio is 5.60, the price to book ratio is 41.74.
Transactions by insiders
Recent insider trading involved KCK LTD., 10% Owner, that happened on Feb 20 ’25 when 5.27 million shares were sold. CHIEF MEDICAL OFFICER, Morrell Martha completed a deal on Jan 30 ’25 to sell 200.0 shares. Meanwhile, CHIEF MEDICAL OFFICER Morrell Martha sold 100.0 shares on Jan 29 ’25.
